Bharat Biotech and GSK cut the world’s first malaria vaccine under $ 5
India Biotech and GSK announced a price reduction for the world’s first malaria vaccine, which is less than $ 5. The move aims to improve and save thousands of children in malaria-sustainable countries.
In short
- The price of the world’s first malaria vaccine has come down by $ 5
- Manufacturing reforms enable cost effective production
- The vaccine rollout is supported by Gavi and many global partners
Hyderabad-based drug manufacturers Bharat Biotech and GSK have announced that the price of the world’s first malaria vaccine, RTS, S, will be reduced by $ 5 for children in malaria-slander countries.
This price cut is expected to improve access to the vaccine and can save thousands of young lives every year.
The announcement made on Wednesday, part of the pledge of companies for the Gavi vaccine alliance for its 2026–2030 phase. The lower price will gradually apply and will be fully implemented by 2028.
India Biotech says that this price fall is possible due to improvement in manufacturing, large production capacity, cost -effective processes and a commitment to keep the profit margin.
World’s first malaria vaccine
RTS is the first malaria vaccine in the world recommended by the World Health Organization (WHO). Since its recommendation in 2021, GSK has invested heavily in improving production and transferring manufacturing technology to Bharat Biotech.
In turn, Bharat Biotech has invested over $ 200 million in new, high-output features and product development.
By the end of 2025, the vaccine is expected to be part of regular vaccination programs in 12 African countries, with the support of Gavi.
These efforts are supported by cooperation between GSK, Bharat Biotech, Joe, Path, Medacus and Malaria affected countries.
Executive Chairman of India Biotech, Dr. Krishna Ella said, “This pledge is more than a price cut – this is a commitment to global equity. We are working to close the gap between the immediate needs of children in the supply of vaccine and the risk of malaria.”
“We have worked closely with India Biotech and our colleagues to make this vaccine more economical and accessible. Today’s announcement is a big step towards changing the future of malaria prevention,” said Thomas Breaur said, “We have worked closely to make this vaccine more economical and accessible.”
For families and communities in areas where malaria has taken heavy toll, vaccine cost reduction can help control global efforts and eventually eliminate the disease.
